MedPath

F. Hoffmann-La Roche Ltd

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2.3k

Active:2221
Completed:38

Trial Phases

4 Phases

Phase 1:1725
Phase 2:4
Phase 3:14
+1 more phases

Drug Approvals

3

NMPA:1
SFDA:1
NPRA:1

Drug Approvals

Satralizumab Injection

Product Name
安适平
Approval Number
国药准字SJ20210017
Approval Date
Apr 30, 2021
NMPA

Clinical Trials

Distribution across different clinical trial phases (1748 trials with phase data)• Click on a phase to view related trials

Phase 1
1725 (98.7%)
Phase 3
14 (0.8%)
Not Applicable
5 (0.3%)
Phase 2
4 (0.2%)
No trials found

News

Supreme Court Questions Roche on High Pricing of SMA Drug Risdiplam in India

The Supreme Court of India has issued a notice to F. Hoffmann-La Roche Ltd regarding the pricing of Risdiplam, a medication for Spinal Muscular Atrophy (SMA), questioning why it's more expensive in India than neighboring countries.

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as New Chief Medical Officer

Neurocrine Biosciences has appointed Dr. Sanjay Keswani as Chief Medical Officer effective June 2, 2025, succeeding Dr. Eiry W. Roberts who served in the role for seven years.

Atezolizumab Fails to Improve Progression-Free Survival in Recurrent Ovarian Cancer

A phase III trial (ENGOT-OV41/GEICO 69-O/ANITA) assessed atezolizumab with platinum-based chemotherapy and niraparib maintenance in recurrent ovarian cancer patients.

HER2DX® Genomic Test Demonstrates Predictive Value in Advanced HER2+ Breast Cancer

REVEAL GENOMICS' HER2DX® test shows a significant association between ERBB2 mRNA levels and survival outcomes in HER2+ breast cancer patients treated with standard therapies.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.